

# Age-related changes in the upper respiratory microbiome are associated with SARS-CoV-2 susceptibility and illness severity

Jillian H. Hurst, PhD<sup>1,2</sup>, Alexander W. McCumber, MS<sup>3</sup>, Jhoanna N. Aquino, BS<sup>1</sup>, Javier Rodriguez, AS<sup>4</sup>, Sarah M. Heston, MD<sup>1</sup>, Debra J. Lugo, MD<sup>1</sup>, Alexandre T. Rotta, MD<sup>5</sup>, Nicholas A. Turner, MD, MHSc<sup>6</sup>, Trevor S. Pfeiffer, BS<sup>1</sup>, Thaddeus C. Gurley, MS<sup>7</sup>, M. Anthony Moody, MD<sup>1,7</sup>, Thomas N. Denny, MSc, MPhil<sup>7</sup>, John F. Rawls, PhD<sup>8,9</sup>, Christopher W. Woods, MD, MPH<sup>6,7</sup>, Matthew S. Kelly, MD, MPH<sup>1,9</sup>

<sup>1</sup>Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA; <sup>2</sup>Children's Health and Discovery Institute, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA; <sup>3</sup>Civil and Environmental Engineering Department, Duke University, Durham, North Carolina, USA; <sup>4</sup>Children's Clinical Research Unit, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA; <sup>5</sup>Department of Pediatrics, Division of Pediatric Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina, USA; <sup>6</sup>Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA; <sup>7</sup>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA; <sup>8</sup>Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA; <sup>9</sup>Duke Microbiome Center, Duke University School of Medicine, Durham, North Carolina, USA

**Summary:** Evaluation of nasopharyngeal microbiome profiles in children, adolescents, and young adults with a SARS-CoV-2-infected close contact identified specific bacterial species that vary in abundance with age and are associated with SARS-CoV-2 susceptibility and the presence of SARS-CoV-2-associated respiratory symptoms.

1 **Keywords:** COVID-19; community; pediatric; children; nasopharyngeal microbiome; *Corynebacterium*;

2 *Dolosigranulum*

3

4 **Corresponding Author:**

5 Matthew S. Kelly, MD, MPH

6 2301 Erwin Road

7 Durham, NC 27710

8 Phone: (919) 684-6335

9 Email: [matthew.kelly@duke.edu](mailto:matthew.kelly@duke.edu)

1 **ABSTRACT**

2

3 Children are less susceptible to SARS-CoV-2 and typically have milder illness courses than adults. We  
4 studied the nasopharyngeal microbiomes of 274 children, adolescents, and young adults with SARS-CoV-  
5 2 exposure using 16S rRNA gene sequencing. We find that higher abundances of *Corynebacterium*  
6 species are associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory symptoms,  
7 while higher abundances of *Dolosigranulum pigrum* are present in SARS-CoV-2-infected individuals  
8 *without* respiratory symptoms. We also demonstrate that the abundances of these bacteria are strongly,  
9 and independently, associated with age, suggesting that the nasopharyngeal microbiome may be a  
10 potentially modifiable mechanism by which age influences SARS-CoV-2 susceptibility and severity.

11

1 SARS-CoV-2, the etiological agent of coronavirus disease 2019 (COVID-19), has resulted in more than  
2 100 million infections and two million deaths globally [1]. In contrast to most other respiratory viruses [2-  
3 4], children appear to be less susceptible to SARS-CoV-2 infection, and SARS-CoV-2-infected children  
4 typically have milder illness courses than adults. In a recent meta-analysis that included 32 studies of  
5 41,640 children and adolescents less than 20 years of age and 268,945 adults 20 years of age or older,  
6 children and adolescents were estimated to have a 46% lower susceptibility to SARS-CoV-2 infection  
7 than adults [5]. Further, a higher incidence of SARS-CoV-2 infection has been observed with increasing  
8 age, even among infants, children, and adolescents [6]. Reporting data from a community-based study of  
9 SARS-CoV-2 infections, we previously demonstrated that at least one-third of SARS-CoV-2-infected  
10 children and adolescents are asymptomatic [7], and children who do develop symptomatic SARS-CoV-2  
11 infection typically report mild respiratory symptoms [7-10]. Additionally, COVID-19 hospitalization rates  
12 and mortality among children are substantially lower than among adults of all ages, with only 576  
13 hospitalizations and 208 deaths among children and adolescents less than 18 years of age reported during  
14 the first six months of the pandemic in the United States [11]. These data suggest that host biological or  
15 immunological factors that vary with age modify susceptibility to and severity of SARS-CoV-2 infection,  
16 and that an understanding of these host factors could inform development of novel strategies to prevent or  
17 treat SARS-CoV-2 infections in children and adults.

18  
19 Given that the upper respiratory microbiome undergoes substantial shifts in early childhood [12-14], and  
20 is increasingly recognized to play a key role in the pathogenesis of respiratory virus infections [15-21], we  
21 hypothesized that changes in the upper respiratory microbiome with age might contribute to the  
22 differences in susceptibility to SARS-CoV-2 infection and the severity of SARS-CoV-2-associated  
23 respiratory symptoms among children and adults. In this study, we used 16S ribosomal RNA (rRNA)  
24 gene amplicon sequencing to characterize the nasopharyngeal microbiomes of 274 children, adolescents,  
25 and young adults with close contact with a SARS-CoV-2-infected individual. We describe associations

1 between the composition of the nasopharyngeal microbiome and SARS-CoV-2 infection. In addition, we  
2 identify bacterial species that are associated with the presence of respiratory symptoms among children  
3 with SARS-CoV-2 infection. Finally, we demonstrate that the relative abundances of these bacterial  
4 species within the nasopharyngeal microbiome are strongly, and independently, associated with age.  
5 Taken together, our findings demonstrate that age-associated changes in the upper respiratory microbiome  
6 may contribute to the varied susceptibility to and severity of SARS-CoV-2 infection among children and  
7 adults.

8

## 9 **METHODS**

10

### 11 *Study Population*

12 The Duke Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) study is a prospective  
13 cohort study of children, adolescents, and young adults with confirmed SARS-CoV-2 infection or close  
14 contact with an individual with confirmed SARS-CoV-2 infection [7]. This study is being conducted  
15 within the Duke University Health System in Raleigh-Durham, North Carolina. Eligible participants are  
16 less than 21 years of age and have close contact with an individual with SARS-CoV-2 infection  
17 confirmed by real-time PCR. Close contact is defined as an unprotected exposure within 6 feet to a  
18 confirmed case between 2 days before and 7 days after symptom onset or confirmation of SARS-CoV-2  
19 infection in asymptomatic contacts. Close contacts include, but are not limited to, parents, siblings, other  
20 caregivers, and partners.

21

### 22 *Study Procedures*

23 We collected exposure, sociodemographic, and clinical data at enrollment through review of electronic  
24 medical records and a directed questionnaire conducted by telephone. We recorded any symptoms  
25 reported within the 2 weeks preceding study enrollment. In addition, we conducted follow-up

1 questionnaires for all participants 7 days after study enrollment to document new symptoms and  
2 healthcare encounters. For participants with one or more symptoms 7 days after study enrollment,  
3 additional questionnaires were administered 14 and 28 days after enrollment, or until the participant  
4 reported complete symptom resolution. We recorded the results of SARS-CoV-2 testing performed for  
5 clinical care. In addition, we conducted a home visit as soon as possible after study enrollment to collect a  
6 nasopharyngeal swab and other biospecimens. Participants who declined a home visit received a kit for  
7 self-collection of a mid-turbinate nasal swab. Nasopharyngeal and nasal samples were collected with  
8 nylon flocked swabs (Copan Italia, Brescia, Italy) and placed into RNAProtect (Qiagen, Hilden,  
9 Germany) prior to storage at -80°C. All nasopharyngeal and nasal samples were tested for SARS-CoV-2  
10 using a real-time quantitative PCR assay, as previously described [7]. We classified participants as SARS-  
11 CoV-2-infected if SARS-CoV-2 was identified in either a clinical or research PCR assay. We considered  
12 SARS-CoV-2-infected individuals as having respiratory symptoms if they reported cough, rhinorrhea,  
13 nasal congestion, shortness of breath, sore throat, or anosmia at any point between 14 days prior to  
14 enrollment through the end of the study follow-up period. Finally, we classified participants into one of  
15 three groups: 1) SARS-CoV-2-uninfected; 2) SARS-CoV-2-infected *without* respiratory symptoms; and  
16 3) SARS-CoV-2-infected *with* respiratory symptoms. The analyses presented herein were limited to study  
17 participants with an available nasopharyngeal sample.

18

### 19 *Processing of nasopharyngeal samples for 16S ribosomal RNA sequencing*

20 The Duke Microbiome Core Facility extracted DNA from nasopharyngeal samples using Powersoil Pro  
21 extraction kits (Qiagen) following the manufacturer's instructions. DNA concentrations were determined  
22 using Qubit dsDNA high-sensitivity assay kits (Thermo Fisher Scientific). Bacterial community  
23 composition was characterized by PCR amplification of the V4 variable region of the 16S rRNA gene  
24 using the forward primer 515 and the reverse primer 806 following the Earth Microbiome Project protocol  
25 [22]. These primers carry unique barcodes that allow for multiplexed sequencing. Equimolar 16S rRNA

1 PCR products from all samples were quantified and pooled prior to sequencing. Sequencing was  
2 performed by the Duke Sequencing and Genomic Technologies Core Facility on an Illumina MiSeq  
3 instrument configured for 250 base-pair paired-end sequencing. All samples were included in a single  
4 sample processing run with inclusion of both negative extraction and PCR controls. We analyzed raw  
5 sequences through a DADA2 pipeline [23] and assigned taxonomy to amplicon sequence variants (ASVs)  
6 using Silva SSU version 138 [24]. We identified and removed sequencing contaminants (n=40) using the  
7 *decontam* R package [25]. Samples with less than 1000 sequencing reads after quality filtering and  
8 contaminant removal were excluded. We obtained a median [interquartile range (IQR)] of 24,422 (17,799,  
9 33,291) high-quality sequencing reads from the 274 samples included in these analyses. Sequencing reads  
10 were classified into 1,799 ASVs representing 316 bacterial genera from 20 phyla (**Supplemental Table**  
11 **1**). We performed standard nucleotide REFSEQ BLAST searches of ASV reference sequences using the  
12 National Center for Biotechnology Information's Bacteria and Archaea 16S ribosomal RNA project  
13 database [26]. We assigned species information to ASVs using a best-hit approach based on the E value  
14 with a minimum percent identity of 99%.

## 15

### 16 *Data Analysis*

17 We first sought to characterize changes in nasopharyngeal microbiome diversity and composition that  
18 occur with age. We calculated nasopharyngeal microbiome alpha (Shannon and Chao1 indices) and beta  
19 diversity (Bray-Curtis dissimilarity) using the *phyloseq* R package [27]. We then fit linear regression  
20 models to evaluate associations between participant age and microbiome alpha diversity measures. The  
21 Chao1 index was not normally distributed and was thus log-transformed for these analyses. We then  
22 evaluated the association between age and nasopharyngeal microbiome composition with PERMANOVA  
23 using the *adonis* function within the *vegan* R package [28]. Finally, we used ANCOM-II [29] to fit linear  
24 models evaluating associations between age and the relative abundances of bacterial ASVs within the  
25 nasopharyngeal microbiome. An ASV was considered to be differentially abundant if it varied across the

1 independent variable of interest with respect to 80% of the other ASVs in the dataset ( $W$  statistic  $> 0.80$ ).  
2 ASVs that were identified as structural zeros were not considered to be differentially abundant. All  
3 analyses of nasopharyngeal microbiome diversity and composition by age were adjusted for participant  
4 SARS-CoV-2 infection status and the presence of SARS-CoV-2-associated respiratory symptoms. We  
5 then used these same methods to evaluate associations between nasopharyngeal microbiome diversity and  
6 composition and SARS-CoV-2 infection status, adjusting for participant age. Finally, in analyses limited  
7 to SARS-CoV-2-infected individuals, we used these same methods to evaluate associations between the  
8 nasopharyngeal microbiome and the presence of respiratory symptoms among SARS-CoV-2-infected  
9 participants, adjusting for age. Our findings were not substantively changed when we additionally  
10 adjusted for sex and race in analyses of nasopharyngeal microbiome diversity and composition by age,  
11 SARS-CoV-2 status, or SARS-CoV-2-associated respiratory symptoms. Given that ANCOM-II produces  
12 only a list of differentially abundant ASVs, we used DESeq2 [30] to generate log<sub>2</sub>-fold changes in  
13 abundance in order to determine the directionality of these associations. Analyses conducted in ANCOM-  
14 II and DESeq2 were limited to ASVs present in at least 5% of samples and adjusted for the false  
15 discovery rate using the Benjamini-Hochberg procedure. Analyses were performed using R version 4.0.3  
16 [31] and all visualizations were created using the *ggplot2* R package [32].

17

## 18 **RESULTS**

19

### 20 *Characteristics of the study population*

21 Two hundred seventy-four children, adolescents, and young adults were included in these analyses (**Table**  
22 **1**). Participants were classified as SARS-CoV-2-uninfected (n=75, 27%); SARS-CoV-2-infected *without*  
23 respiratory symptoms (n=88, 32%); and SARS-CoV-2-infected *with* respiratory symptoms (n=111, 41%).  
24 Among SARS-CoV-2-infected individuals, nasopharyngeal samples were collected a median (IQR) of 5  
25 (2, 8) days from symptom onset (or SARS-CoV-2 diagnosis in asymptomatic cases). SARS-CoV-2-



1 infected participants *with* respiratory symptoms were older than SARS-CoV-2-infected participants  
2 without respiratory symptoms and SARS-CoV-2-uninfected participants, consistent with our previous  
3 observation of a high prevalence of respiratory symptoms among SARS-CoV-2-infected adolescents in  
4 this cohort [7]. Similarly, a higher proportion of SARS-CoV-2-infected individuals identified as Latino or  
5 Hispanic-American compared to SARS-CoV-2-uninfected individuals [7]. There were no significant  
6 differences in the prevalences of comorbidities or recent receipt of antibiotics or probiotics in these  
7 groups.

8

### 9 *Age-associated changes in nasopharyngeal microbiome composition*

10 Median (IQR) Shannon diversity and Chao1 indices of the nasopharyngeal microbiome were 1.49 (1.12,  
11 2.00) and 70.0 (48.8, 97.2), respectively. Nasopharyngeal microbiome diversity, as measured by the  
12 Shannon diversity index, increased with age (**Figure 1a**;  $p < 0.0001$ ), while nasopharyngeal microbiome  
13 richness, as measured by the Chao1 index, declined with increasing age (**Figure 1b**;  $p = 0.02$ ). The  
14 composition of the nasopharyngeal microbiome also differed according to age (**Figure 1c**;  
15 PERMANOVA on Bray-Curtis dissimilarity,  $p < 0.001$ ,  $R^2 = 0.103$ ). In particular, older age was associated  
16 with lower abundances of several ASVs classified as *Dolosigranulum*, *Moraxella*, and *Streptococcus*, and  
17 higher abundances of specific ASVs classified as *Anaerococcus*, *Corynebacterium*, *Lawsonella*,  
18 *Peptoniphilus*, and *Staphylococcus* (**Figure 2** and **Supplemental Table 2**). Infants and young children 5  
19 years of age or younger tended to have high abundances of *Dolosigranulum* and *Moraxella* within their  
20 nasopharyngeal microbiomes, while the nasopharyngeal microbiomes of adolescents and young adults 12  
21 years of age or older were frequently dominated by *Staphylococcus*. Additionally, several bacterial genera  
22 (*Anaerococcus*, *Lawsonella*, and *Peptoniphilus*) that were of low prevalence and abundance in the  
23 nasopharyngeal microbiomes of infants and young children were highly abundant in adolescents and  
24 young adults (**Supplemental Table 3**). *Corynebacterium* was highly abundant in the nasopharyngeal  
25 microbiome across all age categories and its relative abundance was positively correlated with age.

1

2 *Associations between the nasopharyngeal microbiome and SARS-CoV-2 susceptibility*

3 Nasopharyngeal microbiome diversity, as measured by the Shannon diversity index, did not differ in  
4 SARS-CoV-2-infected and SARS-CoV-2-uninfected participants (**Figure 1a**;  $p=0.36$ ). In contrast, SARS-  
5 CoV-2-infected individuals had higher microbiome richness, measured by the log-transformed Chao1  
6 index, than uninfected individuals (**Figure 1b**;  $p=0.008$ ). Additionally, nasopharyngeal microbiome  
7 composition differed in SARS-CoV-2-infected and uninfected participants (**Figure 1c**; PERMANOVA on  
8 Bray-Curtis dissimilarity,  $p=0.007$ ,  $R^2=0.009$ ). In ANCOM-II analyses adjusting for age, we identified  
9 two ASVs assigned to the bacterial genus *Corynebacterium* that were differentially abundant by SARS-  
10 CoV-2 infection status (**Figure 3a** and **Supplemental Table 4**), both of which were of higher abundance  
11 in SARS-CoV-2-infected participants relative to uninfected participants. Using BLAST searches, we  
12 operationally classified these ASVs as *Corynebacterium accolens/macginleyi/tuberculostearicum*.  
13 Notably, the relative abundances of both of these ASVs increased with increasing age independent of  
14 SARS-CoV-2 infection status (**Figure 3b** and **Supplemental Table 2**).

15

16 *Associations between the nasopharyngeal microbiome and SARS-CoV-2-associated respiratory symptoms*

17 SARS-CoV-2 infection results in a broad range of clinical manifestations from completely asymptomatic  
18 to severe pneumonia and acute respiratory distress syndrome [33-35]. In particular, we previously  
19 reported marked differences in the prevalences of respiratory symptoms among children, adolescents, and  
20 young adults with SARS-CoV-2 infection [7]. To evaluate the extent to which the upper respiratory  
21 microbiome contributes to the varied clinical presentations of SARS-CoV-2 infection by age, we  
22 compared the nasopharyngeal microbiomes of SARS-CoV-2-infected participants *with* respiratory  
23 symptoms to those of SARS-CoV-2-infected participants *without* respiratory symptoms. Nasopharyngeal  
24 microbiome alpha diversity (Shannon diversity, Chao1 richness) was similar in SARS-CoV-2-infected  
25 individuals with or without respiratory symptoms (**Figure 1a** and **Figure 1b**), while nasopharyngeal

1 microbiome composition differed between these groups (**Figure 1c**; PERMANOVA on Bray-Curtis  
2 dissimilarity,  $p=0.008$ ,  $R^2=0.014$ ). In ANCOM-II analyses adjusting for age, we identified nine ASVs that  
3 were differentially abundant in SARS-CoV-2-infected participants with or without respiratory symptoms  
4 (**Figure 4a** and **Supplemental Table 5**). The two ASVs classified as *Corynebacterium* that were  
5 associated with SARS-CoV-2 infection status (ASV 1017, ASV 1030) were also more abundant in SARS-  
6 CoV-2-infected individuals *with* respiratory symptoms compared to SARS-CoV-2-infected individuals  
7 *without* respiratory symptoms. Additionally, two other *Corynebacterium* ASVs that were identified as  
8 *Corynebacterium accolens/macginleyi/tuberculostearicum* (ASV 1014, ASV 1032) were more abundant  
9 in SARS-CoV-2-infected participants *with* respiratory symptoms. Other ASVs that were more abundant in  
10 SARS-CoV-2-infected participants *with* respiratory symptoms were classified as *Lawsonella*  
11 *clevelandensis* (ASV 1060), *Fingoldia magna* (ASV 1535), *Anaerococcus* spp. (ASV 1593) and  
12 *Peptoniphilus* spp. (ASV 1618). Each of the ASVs that were associated with the presence of respiratory  
13 symptoms in SARS-CoV-2-infected individuals were independently and positively associated with  
14 increasing age (**Figure 4b** and **Supplemental Table 2**), with several ASVs that were almost exclusively  
15 detected in adolescents 12 years of age or older. We also identified a single ASV that was assigned to  
16 *Dolosigranulum pigrum* (ASV 1491) that was of lower abundance in SARS-CoV-2-infected participants  
17 with respiratory symptoms and additionally declined in abundance with increasing age. Finally,  
18 nasopharyngeal microbiome composition also differed between SARS-CoV-2-infected participants *with*  
19 respiratory symptoms and SARS-CoV-2-uninfected participants (PERMANOVA on Bray-Curtis  
20 dissimilarity,  $p<0.001$ ,  $R^2=0.015$ ), with several of these same *Corynebacterium* ASVs (ASV 1017, ASV  
21 1030, ASV 1032) and ASVs classified as *Anaerococcus* spp. (ASV 1582) and *Peptoniphilus* spp. (ASV  
22 1618) being more abundant in the nasopharyngeal microbiomes of SARS-CoV-2-infected participants  
23 *with* respiratory symptoms (**Supplemental Table 6**).

24

25 **DISCUSSION**

1

2 In this study, we found that higher abundances of specific *Corynebacterium* ASVs are associated with  
3 SARS-CoV-2 infection among children, adolescents, and young adults with a SARS-CoV-2-infected  
4 close contact. In addition, we identified nasopharyngeal microbiome alterations, including higher  
5 abundances of *Corynebacterium* and lower abundances of *D. pigrum*, that are associated with the  
6 presence of respiratory symptoms in the setting of confirmed SARS-CoV-2 infection. Finally, we  
7 demonstrate that these same microbiome features are strongly, and independently, associated with  
8 increasing age. Our findings suggest that the upper respiratory microbiome may be a previously  
9 unrecognized and potentially modifiable mechanism by which age influences SARS-CoV-2 susceptibility  
10 and illness severity.

11

12 Over the past several decades, accumulating data have emerged demonstrating that the upper respiratory  
13 microbiome plays a key role in the pathogenesis of respiratory virus infections. First, several studies  
14 indicate that the upper respiratory microbiome modifies susceptibility to respiratory virus infections, as  
15 has been most clearly demonstrated for influenza viruses through household transmission studies [15, 16].  
16 Among 436 household contacts in one of these studies, higher abundances of *Streptococcus* spp. and  
17 *Prevotella salivae* within the nasal/oropharyngeal microbiome were associated with lower susceptibility  
18 to influenza A infection [15]. Additionally, the upper respiratory microbiome may also influence the  
19 symptoms experienced by individuals when respiratory virus infection does occur, presumably through  
20 modulation of the host immune response [36]. For instance, the nasopharyngeal microbiome appears to  
21 modify the severity of respiratory syncytial virus (RSV) infection among young children, with several  
22 studies reporting that higher abundances of *Haemophilus* species are associated with a more exuberant  
23 host immune response to RSV [17-19]. Nasopharyngeal microbiome profiles are also associated with the  
24 levels of inflammatory cytokines in nasal wash samples and the development of symptomatic infection in  
25 adults following experimental rhinovirus challenge [20, 21]. Additionally, intranasal administration of

1 live bacterial strains has been shown to directly modulate immune responses to influenza viruses and RSV  
2 in animal models [37-40]. While data from clinical studies are currently lacking, this work illustrates the  
3 potential that targeted manipulation of the upper respiratory microbiome holds for the prevention and  
4 treatment of respiratory virus infections.

5  
6 To date, studies of the upper respiratory microbiome and SARS-CoV-2 infection have been conducted  
7 among small cohorts of adults presenting with clinical suspicion of COVID-19. De Maio and colleagues  
8 did not find any differences in the nasopharyngeal microbiomes of 18 individuals with symptomatic  
9 SARS-CoV-2 infection and 22 individuals with acute respiratory symptoms who tested negative for  
10 SARS-CoV-2 [41]. Conversely, a study of 59 adults identified several ASVs that were differentially  
11 abundant in those with SARS-CoV-2 infection and in those with higher viral loads during COVID-19,  
12 including higher abundances of ASVs classified as *Peptoniphilus lacrimalis*, *Prevotella copri*, and  
13 *Anaerococcus* spp. [42]. By comparison, Mostafa and colleagues reported lower nasopharyngeal  
14 microbial diversity, a lower abundance of the bacterial family Propionibacteriaceae, and a higher  
15 abundance of *Corynebacterium accolens* in 40 SARS-CoV-2-infected adults compared to 10 SARS-CoV-  
16 2-uninfected adults with suspected COVID-19 [43]. Consistent with findings from this latter study, and in  
17 the largest cohort studied to date, here we demonstrated that ASVs assigned to *Corynebacterium* spp. (*C.*  
18 *accolens/macginleyi/tuberculostearicum*) were associated with SARS-CoV-2 infection among 274  
19 children, adolescents, and adults with SARS-CoV-2 exposure. In addition, we identified novel  
20 associations between ASVs assigned to *Corynebacterium* spp., *Lawsonella clevelandensis*, *Fingoldia*  
21 *magna*, *Anaerococcus* spp., *Peptoniphilus* spp., and *Dolosigranulum pigrum* and the presence of  
22 respiratory symptoms during SARS-CoV-2 infection. Notably, the changes in relative abundances of  
23 these ASVs that were associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory  
24 symptoms were also independently associated with increasing age, suggesting that age-associated changes

1 in the upper respiratory microbiome may underlie the differences in SARS-CoV-2 susceptibility and  
2 illness severity that exist between children and adults.

3

4 Non-*diphtheriae* *Corynebacterium* species and *D. pigrum* were previously shown to have important  
5 microbial interactions within the human nasopharynx. In particular, the abundance of *Corynebacterium*  
6 within the nasopharyngeal microbiome has been negatively associated with colonization by *Streptococcus*  
7 *pneumoniae* among infants and children [44-47], while the relative abundance of *D. pigrum* within the  
8 nasopharyngeal microbiome has been negatively associated with the co-occurrence of both *S. pneumoniae*  
9 and *S. aureus* [47, 48]. Few prior clinical studies identified associations between these bacterial species  
10 and the risk and severity of respiratory virus infections. Interestingly, strains of *Corynebacterium* spp. and  
11 *D. pigrum* have been shown to influence innate immune responses to influenza and RSV in murine  
12 models [49-51], suggesting that these bacterial commensals may influence overall immunological tone  
13 within the upper respiratory tract. Importantly, much of the work on these bacterial species has been  
14 conducted in young children [44-48], and surprisingly little is known about the abundances and functions  
15 of these microbes in the upper respiratory tracts of adults. Taken together, these studies suggest that  
16 specific strains of commensal bacteria have differential impacts on host immune responses to potential  
17 pathogens and that age-associated changes in the relative abundance of different species likely plays a  
18 critical role in infection susceptibility.

19

20 Previous studies demonstrated that the nasopharyngeal microbiome is a relatively low-diversity ecological  
21 niche in young children and older adults. Importantly, relatively few bacterial genera comprise the  
22 majority of the nasopharyngeal microbiome during infancy and early childhood, with microbiome  
23 composition being influenced by breastfeeding [14, 52], mode of delivery [53, 54], acute respiratory  
24 infections [12], antibiotic treatment [12], and season [55]. Studies of older children and adolescents have  
25 primarily focused on the nasopharyngeal microbiome of individuals with asthma and other chronic

1 respiratory diseases [56-59]. Pérez-Losada and colleagues profiled the nasopharyngeal microbiomes of 40  
2 children and adolescents 6-17 years of age with asthma, and found that the most abundant genera were  
3 *Moraxella*, *Staphylococcus*, *Dolosigranulum*, *Corynebacterium*, *Prevotella*, and *Streptococcus* [60].  
4 Several of these bacterial genera are reported to be highly abundant in the nasopharyngeal microbiomes of  
5 healthy adults and adults with asthma [61, 62]. To our knowledge, there are no prior studies that evaluated  
6 upper respiratory microbiome profiles from infancy through early adulthood. Our findings demonstrate  
7 that the nasopharyngeal microbiome continues to develop throughout childhood and adolescence. Future  
8 studies should investigate the biological or environmental factors that contribute to the shifts in  
9 microbiome composition that occur after early childhood.

10

11 Our study had several limitations. First, nasopharyngeal samples were collected at a single time point, and  
12 we did not have nasopharyngeal samples prior to infection in SARS-CoV-2-infected participants.  
13 Therefore, we were unable to determine if the differences in nasopharyngeal microbiome composition  
14 observed by SARS-CoV-2 infection status preceded, or were the consequence of, SARS-CoV-2 infection.  
15 Secondly, all of the SARS-CoV-2-infected study participants had relatively mild symptoms, and no study  
16 participants required antiviral treatment or hospitalization. We therefore were unable to evaluate if the  
17 microbiome features that we identified as being associated with SARS-CoV-2 respiratory symptoms are  
18 additionally associated with severe COVID-19. In addition, our use of 16S rRNA gene amplicon  
19 sequencing prevented us from evaluating other components of the upper respiratory microbiome,  
20 including viruses and fungi. Additionally, 16S rRNA gene amplicon experiments have several well-  
21 documented biases [63], although we sought to minimize these biases in our study through inclusion of all  
22 samples in a single processing run and use of appropriate negative controls. Finally, although analyses  
23 adjusted for age in evaluating associations between the nasopharyngeal microbiome and SARS-CoV-2  
24 susceptibility and illness severity, residual confounding by unmeasured factors remains possible.

25

1 In conclusion, we found that age-associated changes in the nasopharyngeal microbiome are independently  
2 associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory symptoms among  
3 children, adolescents, and young adults. These findings suggest that development of the nasopharyngeal  
4 microbiome during childhood and adolescence may contribute to the differences in SARS-CoV-2  
5 susceptibility and severity observed by age. Future studies should evaluate the potential of the upper  
6 respiratory microbiome to serve as a therapeutic target for the prevention and treatment of infections  
7 caused by SARS-CoV-2 and other respiratory viruses.



## 1 **ACKNOWLEDGEMENTS**

2

3 We would like to thank the Duke University School of Medicine for use of the Microbiome Core Facility,  
4 which performed the DNA extractions and library preparations for this research, and the Duke  
5 Sequencing and Genomic Technologies Core Facility, which sequenced these libraries. We offer our  
6 sincere gratitude to the children and families who participated in this research.

7

## 8 **DECLARATIONS**

9

### 10 **Ethics approval and consent to participate**

11 This study was approved by the Duke University Health System Institutional Review Board. Written  
12 informed consent was obtained from all participants or their legal guardian.

13

### 14 **Availability of data and materials**

15 The sequencing dataset supporting the conclusions of this study is available in the Sequence Read  
16 Archive (PRJNA703574). The statistical files and script used for data analyses are also publicly available  
17 ([https://github.com/alexmccumber/BRAVE\\_Kids](https://github.com/alexmccumber/BRAVE_Kids)).

18

### 19 **Competing Interests**

20 MSK reports advisory board fees from Adagio Therapeutics, Inc. CWW reports advisory board fees  
21 from Roche Molecular Sciences, non-financial support from bioMérieux and Becton Dickinson, a  
22 research collaboration with Biofire, and is co-founder of Predigen. All other authors have no competing  
23 interests to declare.

24

25

1 **Funding**

2 This work was funded by the Duke University School of Medicine and through grants from the Duke  
3 Microbiome Center, Children’s Miracle Network Hospitals, and the Translating Duke Health Children’s  
4 Health and Discovery Initiative. AWM was supported by a grant from the National Science Foundation  
5 (DGE-1545220). SMH was supported by National Institutes of Health (NIH) training grant (T32-  
6 HD094671). MSK was supported by a NIH Career Development Award (K23-AI135090).

7

8 **Author contributions**

9 JHH, AWM, SMH, MAM, JFR, CWW, and MSK contributed to the study concept and design. JNA, JR,  
10 DJL, ATR, NAT, TSP, TCG, and TND collected the data or assisted with data analysis or interpretation.  
11 JHH, AWM, and MSK drafted the manuscript and all other authors revised it critically for important  
12 intellectual content. All authors approved of the final version of the manuscript.

## REFERENCES

- 1  
2  
3 1. Dong E, Du H, Gardner L. *An interactive web-based dashboard to track COVID-19 in real time.*  
4 *Lancet Infect Dis*; published online Feb 19. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).
- 5 2. Welliver, R.C., *Review of epidemiology and clinical risk factors for severe respiratory syncytial*  
6 *virus (RSV) infection.* *The Journal of pediatrics*, 2003. **143**(5): p. 112-117.
- 7 3. Laurichesse, H., et al., *Epidemiological features of parainfluenza virus infections: laboratory*  
8 *surveillance in England and Wales, 1975–1997.* *European journal of epidemiology*, 1999. **15**(5):  
9 p. 475-484.
- 10 4. Piotrowska, Z., et al., *Rhinoviruses are a major cause of wheezing and hospitalization in children*  
11 *less than 2 years of age.* *The Pediatric infectious disease journal*, 2009. **28**(1): p. 25.
- 12 5. Viner, R.M., et al., *Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents*  
13 *Compared With Adults: A Systematic Review and Meta-analysis.* *JAMA Pediatrics*, 2021. **175**(2):  
14 p. 143-156.
- 15 6. *COVID-19 Stats: COVID-19 Incidence, by Age Group — United States, March 1–November 14,*  
16 *2020.* *MMWR Morb Mortal Wkly Rep* 2021;69:1664. doi:  
17 <http://dx.doi.org/10.15585/mmwr.mm695152a8>.
- 18 7. Hurst, J.H., et al., *SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory*  
19 *Virus-Exposed Kids (BRAVE Kids) Study.* *Clin Infect Dis*, 2020.
- 20 8. Castagnoli, R., et al., *Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection*  
21 *in Children and Adolescents: A Systematic Review.* *JAMA Pediatrics*, 2020. **174**(9): p. 882-889.
- 22 9. Yousaf, A.R., et al., *A prospective cohort study in non-hospitalized household contacts with SARS-*  
23 *CoV-2 infection: symptom profiles and symptom change over time.* *Clin Infect Dis*, 2020.
- 24 10. Han, M.S., et al., *Clinical Characteristics and Viral RNA Detection in Children With Coronavirus*  
25 *Disease 2019 in the Republic of Korea.* *JAMA Pediatr*, 2021. **175**(1): p. 73-80.

- 1 11. Kim, L., et al., *Hospitalization Rates and Characteristics of Children Aged <18 Years*  
2 *Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25,*  
3 *2020. MMWR Morb Mortal Wkly Rep, 2020. 69(32): p. 1081-1088.*
- 4 12. Teo, S.M., et al., *The infant nasopharyngeal microbiome impacts severity of lower respiratory*  
5 *infection and risk of asthma development. Cell host & microbe, 2015. 17(5): p. 704-715.*
- 6 13. Mika, M., et al., *Dynamics of the nasal microbiota in infancy: A prospective cohort study. Journal*  
7 *of Allergy and Clinical Immunology, 2015. 135(4): p. 905-912. e11.*
- 8 14. Biesbroek, G., et al., *Early respiratory microbiota composition determines bacterial succession*  
9 *patterns and respiratory health in children. American journal of respiratory and critical care*  
10 *medicine, 2014. 190(11): p. 1283-1292.*
- 11 15. Tsang, T.K., et al., *Association between the respiratory microbiome and susceptibility to influenza*  
12 *virus infection. Clinical Infectious Diseases, 2020. 71(5): p. 1195-1203.*
- 13 16. Lee, K.H., et al., *The respiratory microbiome and susceptibility to influenza virus infection. PLOS*  
14 *ONE, 2019. 14(1): p. e0207898.*
- 15 17. Chu, C.-Y., et al., *Airway Gene Expression Correlates of Respiratory Syncytial Virus Disease*  
16 *Severity and Microbiome Composition in Infants. The Journal of Infectious Diseases, 2020.*
- 17 18. Ederveen, T.H., et al., *Haemophilus is overrepresented in the nasopharynx of infants hospitalized*  
18 *with RSV infection and associated with increased viral load and enhanced mucosal CXCL8*  
19 *responses. Microbiome, 2018. 6(1): p. 1-13.*
- 20 19. de Steenhuijsen Piters, W.A., et al., *Nasopharyngeal Microbiota, Host Transcriptome and Disease*  
21 *Severity in Children with Respiratory Syncytial Virus Infection. American journal of respiratory*  
22 *and critical care medicine, 2016(ja).*
- 23 20. Lehtinen, M.J., et al., *Nasal microbiota clusters associate with inflammatory response, viral load,*  
24 *and symptom severity in experimental rhinovirus challenge. Scientific Reports, 2018. 8(1): p.*  
25 *11411.*

- 1 21. Allen, E.K., et al., *Characterization of the nasopharyngeal microbiota in health and during*  
2 *rhinovirus challenge*. *Microbiome*, 2014. **2**(1): p. 22.
- 3 22. Gilbert, J.A., et al., *Meeting report: the terabase metagenomics workshop and the vision of an*  
4 *Earth microbiome project*. *Stand Genomic Sci*, 2010. **3**(3): p. 243-8.
- 5 23. Callahan, B.J., et al., *DADA2: high-resolution sample inference from Illumina amplicon data*.  
6 *Nature methods*, 2016. **13**(7): p. 581.
- 7 24. McLaren MR. *Silva SSU taxonomic training data formatted for DADA2 (Silva version 138)*, 2020.  
8 *Available at: <http://doi.org/10.5281/zenodo.3986799>*.
- 9 25. Davis, N.M., et al., *Simple statistical identification and removal of contaminant sequences in*  
10 *marker-gene and metagenomics data*. *Microbiome*, 2018. **6**(1): p. 226.
- 11 26. Camacho, C., et al., *BLAST+: architecture and applications*. *BMC Bioinformatics*, 2009. **10**: p.  
12 421.
- 13 27. McMurdie, P.J. and S. Holmes, *phyloseq: an R package for reproducible interactive analysis and*  
14 *graphics of microbiome census data*. *PloS one*, 2013. **8**(4): p. e61217.
- 15 28. Oksanen, J., et al., *The vegan package*. *Community ecology package*, 2007. **10**(631-637): p. 719.
- 16 29. Kaul, A., et al., *Analysis of microbiome data in the presence of excess zeros*. *Frontiers in*  
17 *microbiology*, 2017. **8**: p. 2114.
- 18 30. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for*  
19 *RNA-seq data with DESeq2*. *Genome Biology*, 2014. **15**(12): p. 550.
- 20 31. *R Core Team (2019). R: A language and environment for statistical computing. R Foundation for*  
21 *Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>*.
- 22 32. *H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016.*
- 23 33. He, X., et al., *Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in*  
24 *China: A Meta-Analysis*. *Front Public Health*, 2020. **8**: p. 561264.


- 1 34. Zhu, J., et al., *Clinical characteristics of 3062 COVID-19 patients: A meta-analysis*. J Med Virol,  
2 2020. **92**(10): p. 1902-1914.
- 3 35. Tenforde, M.W., et al., *Characteristics of adult outpatients and inpatients with COVID-19—11*  
4 *academic medical centers, United States, March–May 2020*. Morbidity and Mortality Weekly  
5 Report, 2020. **69**(26): p. 841.
- 6 36. Pichon, M., B. Lina, and L. Josset, *Impact of the respiratory microbiome on host responses to*  
7 *respiratory viral infection*. Vaccines, 2017. **5**(4): p. 40.
- 8 37. Tomosada, Y., et al., *Nasally administered Lactobacillus rhamnosus strains differentially*  
9 *modulate respiratory antiviral immune responses and induce protection against respiratory*  
10 *syncytial virus infection*. BMC immunology, 2013. **14**(1): p. 40.
- 11 38. Zelaya, H., et al., *Nasal priming with immunobiotic Lactobacillus rhamnosus modulates*  
12 *inflammation–coagulation interactions and reduces influenza virus-associated pulmonary*  
13 *damage*. Inflammation Research, 2015. **64**(8): p. 589-602.
- 14 39. Hori, T., et al., *Effect of intranasal administration of Lactobacillus casei Shirota on influenza*  
15 *virus infection of upper respiratory tract in mice*. Clin Diagn Lab Immunol, 2001. **8**(3): p. 593-7.
- 16 40. Harata, G., et al., *Intranasal administration of Lactobacillus rhamnosus GG protects mice from*  
17 *H1N1 influenza virus infection by regulating respiratory immune responses*. Letters in applied  
18 microbiology, 2010. **50**(6): p. 597-602.
- 19 41. De Maio, F., et al., *Nasopharyngeal microbiota profiling of SARS-CoV-2 infected patients*.  
20 Biological procedures online, 2020. **22**(1): p. 1-4.
- 21 42. Rosas-Salazar, C., et al., *SARS-CoV-2 Infection and Viral Load are Associated with the Upper*  
22 *Respiratory Tract Microbiome*. Journal of Allergy and Clinical Immunology, 2021.
- 23 43. Mostafa, H.H., et al., *Metagenomic next-generation sequencing of nasopharyngeal specimens*  
24 *collected from confirmed and suspect covid-19 patients*. Mbio, 2020. **11**(6).

- 1 44. Kelly, M.S., et al., *The nasopharyngeal microbiota of children with respiratory infections in*  
2 *Botswana*. The Pediatric infectious disease journal, 2017. **36**(9): p. e211.
- 3 45. Bomar, L., et al., *Corynebacterium accolens releases antipneumococcal free fatty acids from*  
4 *human nostril and skin surface triacylglycerols*. MBio, 2016. **7**(1): p. e01725-15.
- 5 46. Khamash, D.F., et al., *The Association Between the Developing Nasal Microbiota of Hospitalized*  
6 *Neonates and Staphylococcus aureus Colonization*. Open Forum Infectious Diseases, 2019. **6**(4).
- 7 47. Laufer, A.S., et al., *Microbial communities of the upper respiratory tract and otitis media in*  
8 *children*. MBio, 2011. **2**(1): p. e00245-10.
- 9 48. Brugger, S.D., et al., *Dolosigranulum pigrum cooperation and competition in human nasal*  
10 *microbiota*. Msphere, 2020. **5**(5).
- 11 49. Ortiz Moyano, R., et al., *The ability of respiratory commensal bacteria to beneficially modulate*  
12 *the lung innate immune response is a strain dependent characteristic*. Microorganisms, 2020.  
13 **8**(5): p. 727.
- 14 50. Kanmani, P., et al., *Respiratory commensal bacteria Corynebacterium pseudodiphtheriticum*  
15 *improves resistance of infant mice to respiratory syncytial virus and Streptococcus pneumoniae*  
16 *superinfection*. Frontiers in microbiology, 2017. **8**: p. 1613.
- 17 51. Mak, N., E. Schiltknecht, and G. Ada, *Protection of mice against influenza virus infection:*  
18 *enhancement of nonspecific cellular responses by Corynebacterium parvum*. Cellular  
19 immunology, 1983. **78**(2): p. 314-325.
- 20 52. Biesbroek, G., et al., *The impact of breastfeeding on nasopharyngeal microbial communities in*  
21 *infants*. American journal of respiratory and critical care medicine, 2014. **190**(3): p. 298-308.
- 22 53. Bosch, A.A., et al., *Development of upper respiratory tract microbiota in infancy is affected by*  
23 *mode of delivery*. EBioMedicine, 2016. **9**: p. 336-345.

- 1 54. Dominguez-Bello, M.G., et al., *Delivery mode shapes the acquisition and structure of the initial*  
2 *microbiota across multiple body habitats in newborns*. Proceedings of the National Academy of  
3 Sciences, 2010. **107**(26): p. 11971-11975.
- 4 55. Bogaert, D., et al., *Variability and diversity of nasopharyngeal microbiota in children: a*  
5 *metagenomic analysis*. Plos one, 2011. **6**(2): p. e17035.
- 6 56. Hilty, M., et al., *Disordered microbial communities in asthmatic airways*. PLoS one, 2010. **5**(1): p.  
7 e8578.
- 8 57. Marri, P.R., et al., *Asthma-associated differences in microbial composition of induced sputum*.  
9 Journal of Allergy and Clinical Immunology, 2013. **131**(2): p. 346-352. e3.
- 10 58. Zhang, Q., et al., *Airway microbiota in severe asthma and relationship to asthma severity and*  
11 *phenotypes*. PLoS one, 2016. **11**(4): p. e0152724.
- 12 59. Hahn, A., et al., *Microbial diversity within the airway microbiome in chronic pediatric lung*  
13 *diseases*. Infection, Genetics and Evolution, 2018. **63**: p. 316-325.
- 14 60. Pérez-Losada, M., et al., *Nasopharyngeal Microbiome Diversity Changes over Time in Children*  
15 *with Asthma*. PLoS One, 2017. **12**(1): p. e0170543.
- 16 61. Stearns, J.C., et al., *Culture and molecular-based profiles show shifts in bacterial communities of*  
17 *the upper respiratory tract that occur with age*. Isme j, 2015. **9**(5): p. 1246-59.
- 18 62. Bomar, L., S.D. Brugger, and K.P. Lemon, *Bacterial microbiota of the nasal passages across the*  
19 *span of human life*. Current opinion in microbiology, 2018. **41**: p. 8-14.
- 20 63. Brooks, J.P., et al., *The truth about metagenomics: quantifying and counteracting bias in 16S*  
21 *rRNA studies*. BMC Microbiology, 2015. **15**(1): p. 66.
- 22



## 1 FIGURES



2

3 **Figure 1. Nasopharyngeal microbiome alpha and beta diversity by age and SARS-CoV-2 clinical**

4 **status.** Shannon diversity (a) and Chao1 richness (b) is shown for each age group by clinical status:


5 SARS-CoV-2-uninfected (green), SARS-CoV-2-infected *without* respiratory symptoms (purple), and

6 SARS-CoV-2-infected *with* respiratory symptoms (orange). Points represent individual samples while the

7 line denotes means for samples from each group in each age category. (c) Non-metric multidimensional


8 scaling plot based on Bray-Curtis distances is shown by age category and according to SARS-CoV-2

1 clinical status [(SARS-CoV-2-uninfected (green), SARS-CoV-2-infected *without* respiratory symptoms  
2 (purple), and SARS-CoV-2-infected *with* respiratory symptoms (orange)]. Within each panel  
3 corresponding to an age category, the colored points represent samples for the corresponding age  
4 category, while the gray points represent samples collected from children in other age categories.  
5




1

2 **Figure 2. Relative abundances of highly abundant genera by age.** Each bar depicts the mean relative  
3 abundances of highly abundant genera in nasopharyngeal samples from participants in a specific age  
4 category. Only the nine most highly abundant genera within nasopharyngeal samples from the entire  
5 study population are shown.




1  
2 **Figure 3. Relative abundances of ASVs that were differentially abundant by SARS-CoV-2 infection**  
3 **status.** a) Boxplots of the relative abundances of ASVs that were differentially abundant by SARS-CoV-2  
4 infection status in age-adjusted analyses conducted in ANCOM-II. a) Boxplots of the relative abundances  
5 by age group of ASVs that were differentially abundant by SARS-CoV-2 infection status in age-adjusted  
6 analyses conducted in ANCOM-II. Relative abundances are plotted on a log scale with 1E-6 added to all  
7 counts to enable transformation of zero counts. Rectangles represent the lower quartile, median, and upper  
8 quartile of the relative abundances of each ASV. The relative abundances of two ASVs classified as  
9 *Corynebacterium accolens/macginleyi/tuberculostearicum* were higher in SARS-CoV-2-infected  
10 individuals compared to uninfected individuals, adjusting for age (ASV 1017,  $W=192$ ; ASV 1030,  
11  $W=233$ ). In addition, the relative abundances of these *Corynebacterium* ASVs increased with increasing  
12 age adjusting for SARS-CoV-2 infection status and the presence of SARS-CoV-2-associated respiratory  
13 symptoms (ASV 1017,  $W=170$ ; ASV 1030,  $W=173$ ).

a



b



1  
2 **Figure 4. Relative abundances of ASVs that were differentially abundant by SARS-CoV-2-**  
3 **associated respiratory symptoms.** a) Boxplots of the relative abundances of ASVs that were  
4 differentially abundant by the presence of respiratory symptoms in SARS-CoV-2-infected individuals in  
5 age-adjusted analyses performed in ANCOM-II. b) Boxplots of the relative abundances by age group of  
6 ASVs that were differentially abundant by SARS-CoV-2 infection status in age-adjusted analyses

1 conducted in ANCOM-II. Relative abundances are plotted on a log scale with 1E-6 added to all counts to  
2 enable transformation of zero counts. Rectangles represent the lower quartile, median, and upper quartile  
3 of the relative abundances of each ASV. Adjusting for age, SARS-CoV-2-associated respiratory  
4 symptoms were associated with higher abundances of ASVs assigned to *Corynebacterium* spp. (ASV  
5 1014, W=268; ASV 1017, W=233; ASV 1030, W=271; ASV 1032, W=229), *Lawsonella clevelandensis*  
6 (ASV 1060, W=273), *Fingoldia magna* (ASV 1535, W=265), *Anaerococcus* spp. (ASV 1593, W=231),  
7 and *Peptoniphilus* spp. (ASV 1618, W=271). The relative abundances of each of these ASVs additionally  
8 increased with increasing age adjusting for SARS-CoV-2 infection status and the presence of SARS-CoV-  
9 2-associated respiratory symptoms (ASV 1014, W=173; ASV 1017, W=170; ASV 1030, W=173; ASV  
10 1032, W=170; ASV 1060, W=173; ASV 1535, W=172; ASV 1593, W=169; ASV 1618, W=173).  
11 Adjusting for age, SARS-CoV-2-associated respiratory symptoms were associated with a lower  
12 abundance of a single ASV assigned to *Dolosigranulum pigrum* (ASV 1491, W=260), and the relative  
13 abundance of this ASV decreased with increasing age adjusting for SARS-CoV-2 infection status and the  
14 presence of SARS-CoV-2-associated respiratory symptoms (ASV 1491, W=171).

1 **SUPPLEMENTAL MATERIALS**

2

3 **Supplemental Table 1.** Taxonomic classification and reference sequences for ASVs identified in  
4 nasopharyngeal samples from the study population

5

6 **Supplemental Table 2.** Differentially abundant ASVs by age in ANCOM-II analyses adjusting for  
7 SARS-CoV-2-infection status and SARS-CoV-2-associated respiratory symptoms

8

9 **Supplemental Table 3.** Prevalences and relative abundances of highly abundant bacterial genera by age

10

11 **Supplemental Table 4.** Differentially abundant ASVs by SARS-CoV-2 infection status in ANCOM-II  
12 analyses adjusting for age

13

14 **Supplemental Table 5.** Differentially abundant ASVs among SARS-CoV-2-infected individuals by the  
15 presence of respiratory symptoms in ANCOM-II analyses adjusting for age

16

17 **Supplemental Table 6.** Differentially abundant ASVs in analyses comparing SARS-CoV-2-infected  
18 individuals *with* respiratory symptoms to SARS-CoV-2-uninfected individuals in ANCOM-II analyses  
19 adjusting for age

**Table 1.** Characteristics of the study population

	<b>SARS-CoV-2-Exposed, Uninfected (n=75)</b>		<b>SARS-CoV-2-Infected Without Respiratory Symptoms (n=88)</b>		<b>SARS-CoV-2-Infected With Respiratory Symptoms (n=111)</b>		<i>P</i>
	N (or median)	% (or IQR)	N (or median)	% (or IQR)	N (or median)	% (or IQR)	
Age, years	9.2	(5.0–16.7)	9.1	(5.1–14.2)	14.2	(6.5–17.5)	0.006
Female sex	38	51%	49	56%	57	49%	0.77
Race							<0.0001
Black or African-American	3	4%	5	6%	8	7%	
Latino or Hispanic-American	43	57%	77	88%	99	89%	
Non-Hispanic white	29	39%	6	7%	4	4%	
Comorbidities							
Provider-diagnosed asthma	8	11%	6	7%	9	8%	0.67
Obesity (BMI ≥95 <sup>th</sup> percentile for age)	21	28%	21	24%	40	36%	0.16
Receipt of antibiotic in prior 30 days	1	1%	2	2%	3	3%	0.88
Receipt of probiotic in prior 30 days	2	3%	0	0%	1	1%	0.37

IQR, interquartile range; BMI, body mass index